NOTCH1 and B-cell chronic lymphocytic leukemia: The combined effect of AZ1 and venetoclax was most pronounced in primary CLL cells with high expression of NICD and cells with mutations in NOTCH1 (Fig. 8C; Supplementary Table 4).